Q1 FY27 results reported
As filed · Outcome of Board Meeting
EarningsNotablemateriality 72 out of 100
What happened
FactOutcome of Board Meeting. July 23, 2026, have considered and approved the Unaudited Financial Results. A copy of the Unaudited Financial Results along with the Limited Review Report has been.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedEarlierQ1 FY27
excluding the ibuprofen business, the base business delivered a 24% growth on this quarter.
NowQ1 FY27
if you adjust that particular price increase what we had passed through in terms of revenue growth number, so that growth should be coming around to close to 18%, 19% of year-on-year growth as compared to Q1 of '26.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved -25.00%.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- the strategic review of the ibuprofen business would be concluded by the first half of '27. (management committed by H1 FY27)
- we will come up with the next steps in terms of both ibuprofen Vizag, Pondy and what we do with the CRAMS deme (management committed by Q2 FY27)
Evidence
- Outcome of Board Meeting(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%